Browsing by Author "Piedra-Delgado, L"

Now showing 1 - 3 of 3

Correction to: Unveiling Melanoma: A Deep Dive into Disparities at a Latin-American Cancer Institute (Annals of Surgical Oncology, (2024), 31, 9, (6097-6117), 10.1245/s10434-024-15573-6)
(Springer Science and Business Media Deutschland GmbH, 2024) Ziegler-Rodriguez, G; De, La, Cruz-Ku, G; Piedra-Delgado, L; Torres-Maldonado, J; Dunstan, J; Cotrina-Concha, JM; Galarreta-Zegarra, JA; Calderon-Valencia, G; Vilchez-Santillan, S; Pinillos-Portella, M; Möller, MG
In the original online version of this article Luis Piedra‑Delgado's affiliation was incorrect. It is correct as reflected here. The original article was corrected.
Survival according to the site of metastasis in triple-negative breast cancer patients: The Peruvian experience
(Public Library of Science, 2024) Piedra-Delgado, L; Chambergo-Michilot, D; Morante, Z; Fairen, C; Jerves-Coello, F; Luque-Benavides, R; Casas, F; Bustamante, E; Razuri-Bustamante, C; Torres-Roman, JS; Fuentes, H; Gomez, H; Narvaez-Rojas, A; De, La, Cruz-Ku, G; Araujo, J
Background Evidence regarding differences in survival associated with the site of metastasis in triplenegative breast cancer (TNBC) remains limited. Our aim was to analyze the overall survival (OS), distant relapse free survival (DRFS), and survival since the diagnosis of the relapse (MS), according to the side of metastasis. Methods This was a retrospective study of TNBC patients with distant metastases at the Instituto Nacional de Enfermedades Neoplasicas (Lima, Peru) from 2000 to 2014. Prognostic factors were determined by multivariate Cox regression analysis. Results In total, 309 patients were included. Regarding the type of metastasis, visceral metastasis accounted for 41% and the lung was the most frequent first site of metastasis (33.3%). With a median follow-up of 10.2 years, the 5-year DRFS and OS were 10% and 26%, respectively. N staging (N2-N3 vs. N0, HR = 1.49, 95%CI: 1.04-2.14), metastasis in visceral sites (vs. bone; HR = 1.55, 95%CI: 0.94-2.56), the central nervous system (vs. bone; HR = 1.88, 95% CI: 1.10-3.22), and multiple sites (vs. bone; HR = 2.55, 95%CI:1.53-4.25) were prognostic factors of OS whereas multiple metastasis (HR = 2.30, 95% CI: 1.42-3.72) was a predictor of MS. In terms of DRFS, there were no differences according to metastasis type or solid organ. Conclusion TNBC patients with multiple metastasis and CNS metastasis have an increased risk of death compared to those with bone metastasis in terms of OS and MS.
Unveiling Melanoma: A Deep Dive into Disparities at a Latin-American Cancer Institute
(Springer Science and Business Media Deutschland GmbH, 2024) Ziegler-Rodriguez, G; De, La, Cruz-Ku, G; Piedra-Delgado, L; Torres-Maldonado, J; Dunstan, J; Cotrina-Concha, JM; Galarreta-Zegarra, JA; Calderon-Valencia, G; Vilchez-Santillan, S; Pinillos-Portella, M; Möller, MG
Introduction: The worldwide incidence of melanoma has increased in the last 40 years. Our aim was to describe the clinic-pathological characteristics and outcomes of three cohorts of patients diagnosed with melanoma in a Latin-American cancer institute during the last 20 years. Methods: We evaluated three retrospective patient cohorts diagnosed with melanoma at Instituto Nacional de Enfermedades Neoplasicas (INEN), a public hospital in Lima, Peru, for the years 2005–2006, 2010–2011, and 2017–2018. Survival rate differences were assessed using the Log-rank test. Results: Overall, 584 patients were included (only trunk and extremities); 51% were male, the mean age was 61 (3–97) years, and 48% of patients resided in rural areas. The mean time to diagnosis was 22.6 months, and the mean Breslow thickness was 7.4 mm (T4). Lower extremity was the most common location (72%). A majority of the patients (55%) had metastases at the time of presentation, with 36% in stage III and 19% in stage IV. Cohorts were distributed as 2005–2006 (n = 171), 2010–2011 (n = 223), and 2017–2018 (n = 190). No immunotherapy was used. Cohort C exhibited the most significant increase in stage IV diagnoses (12.3%, 15.7%, 28.4%, respectively; p < 0.01). The median overall survival rates at the three-year follow-up demonstrated a decline over the years for stages II (97%, 98%, 57%, respectively; p < 0.05) and III (66%, 77%, 37%; p < 0.01). Conclusions: There has been a worsening in the incidence of late-stage metastatic melanoma in Peru throughout the years, coupled with a significant decline in overall survival rates. This is underscored by the fact that half of the population lives in regions devoid of oncological access.